Form 4: Rapport Therapeutics CEO Sells $323K in Stock

Rapport Therapeutics CEO Abraham Ceesay executed sales of company common stock totaling approximately $323,588 through pre-arranged 10b5-1 trading plans.

Summary

• Abraham Ceesay, CEO and Director of Rapport Therapeutics, Inc. (RAPP), reported sales of common stock on December 17, 2025.
• A total of 10,916 shares were sold, comprising 5,833 shares directly owned and 5,083 shares held indirectly by The Dorothy Ceesay Irrevocable Trust.
• The sales were executed under Rule 10b5-1 trading plans adopted on December 12, 2024.
• The weighted average sale prices for the direct sales ranged from $28.8378 to $31.036 per share.
• The weighted average sale prices for the indirect sales ranged from $28.8425 to $31.0396 per share.
• Following these transactions, Abraham Ceesay directly beneficially owns 567,913 shares.
• The Dorothy Ceesay Irrevocable Trust beneficially owns 30,895 shares, and The Ceesay Family Irrevocable Trust beneficially owns 81,729 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling based on new negative information. It represents a planned financial action rather than a reactive one.

Positives

• The sales were conducted under pre-arranged Rule 10b5-1 trading plans, indicating a planned divestment rather than an immediate reaction to new information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.
• The CEO and a related trust collectively sold 10,916 shares.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing reports routine insider stock sales under a pre-arranged plan, which is a common practice among executives for personal financial planning and diversification. It does not inherently reflect on broader industry trends or competitive positioning within the biotechnology sector, but rather on individual executive compensation and asset management strategies.

Comparison to Industry Standards

• The reported sales are consistent with typical insider trading activities observed across publicly traded companies, particularly when executed under Rule 10b5-1 plans.
• Such plans are standard mechanisms for executives to sell shares in a compliant and pre-scheduled manner, mitigating concerns about trading on material non-public information.
• There are no specific comparable companies or projects mentioned in the filing to provide a direct benchmark.

Related Party Transactions

• Sales of 5,083 shares were made indirectly by The Dorothy Ceesay Irrevocable Trust, which is a related party to Abraham Ceesay.

Stakeholder Impact

• Shareholders may interpret the insider selling as a slight negative, though the 10b5-1 plan context reduces this impact.
• The transactions are part of the CEO's personal financial planning and do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

The insider sales by CEO Abraham Ceesay, while reducing his direct and indirect holdings, were executed under a pre-arranged Rule 10b5-1 trading plan. This suggests a planned diversification or liquidity event rather than a reaction to new material non-public information. Therefore, this specific filing alone does not provide a strong signal for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate as it's a routine, pre-scheduled transaction.

Keywords

Rapport Therapeutics, RAPP, Abraham Ceesay, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Biotechnology, Pharmaceuticals